PolyPid (NASDAQ:PYPD) versus Beta Bionics (NASDAQ:BBNX) Critical Review

PolyPid (NASDAQ:PYPD) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for PolyPid and Beta Bionics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0	0	3	1	3.25
Beta Bionics	0	3	5	1	2.78

PolyPid presently has a consensus target price of $11.33, indicating a potential upside of 286.14%. Beta Bionics has a consensus target price of $24.83, indicating a potential upside of 67.23%. Given PolyPid’s stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than Beta Bionics.

Profitability

This table compares PolyPid and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-624.10%	-129.28%
Beta Bionics	N/A	N/A	N/A

Valuation and Earnings

This table compares PolyPid and Beta Bionics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($4.97)	-0.59
Beta Bionics	$53.03 million	12.00	N/A	N/A	N/A

Beta Bionics has higher revenue and earnings than PolyPid.

Insider & Institutional Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.